CoChat
Sign Up
Cited by 289Pharmacology and Obesity TreatmentBariatric Surgery and OutcomesObesity, Physical Activity, Diet

The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.

Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.

Open access
Hill, James O, Hauptman, Jonathan, Anderson, James W, Fujioka, Ken, O'Neil, Patrick M, Smith, Diane K, Zavoral, James H, Aronne, Louis J·1999·The American Journal of Clinical Nutrition
DOI 10.1093/ajcn/69.6.1108
Open this paper in CoChat — free accountOpen PDF

Abstract

Background Long-term maintenance of weight loss remains a therapeutic challenge in obesity treatment.Objective This multicenter, double-blind, placebo-controlled study was designed to test the hypothesis that orlistat, a gastrointestinal lipase inhibitor, is significantly more effective than a placebo in preventing weight regain.Design Obese subjects who lost > or = 8% of their initial body weight during a 6-mo lead-in of a prescribed hypoenergetic diet (4180-kJ/d deficit) with no adjunctive pharmacotherapy were randomly assigned to receive placebo, 30 mg orlistat, 60 mg orlistat, or 120 mg orlistat 3 times daily for 1 y in combination with a maintenance diet to help prevent weight regain. Of 1313 recruited subjects [body mass index (in kg/m2): 28-43], 729 subjects lost > or =8% of their initial body weight during the 6-mo weight-loss lead-in period and were enrolled in the double-blind phase.Results After 1 y, subjects treated with 120 mg orlistat 3 times daily regained less weight than did placebo-treated subjects (32.8 +/- 4.5% compared with 58.7 +/- 5.8% regain of lost weight; P < 0.001). Moreover, more subjects in the 120-mg orlistat group than in the placebo group regained < or = 25% of lost weight (47.5% of subjects compared with 29.9%). In addition, orlistat treatment (120 mg 3 times daily) was associated with significantly greater reductions in total and LDL-cholesterol concentrations than was placebo (P < 0.001).Conclusion The use of orlistat during periods of attempted weight maintenance minimizes weight readjustment and facilitates long-term improvement in obesity-related disease risk factors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ajcn/69.6.1108

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. 1985, Energy and protein requirement. Report of a joint FAO/WHO/UNU Expert Consultation, World Health Organ Tech Rep Ser, 724

Cited by

Sorted by citations

See all 289

Related

See all

Metadata

Authors
Hill, J. O., Hauptman, J., Anderson, J. W., Fujioka, K., O'Neil, P. M., Smith, D. K., Zavoral, J. H., & Aronne, L. J.
Affiliations
Scripps Health (US)
Corresponding author
Aronne, Louis J
ORCID
Venue
The American Journal of Clinical Nutrition
Publisher
Elsevier BV
Published
1999-06
Volume
69
Issue
6
Pages
1108-1116
ISSN
0002-9165 (ISSN-L)
DOI
10.1093/ajcn/69.6.1108
OpenAlex
W2166266400
Cited by
287
References
26
Citations by year
2026: 3 · 2025: 7 · 2024: 6 · 2023: 5 · 2022: 3 · 2021: 1 · 2020: 4 · 2019: 2 · 2018: 4 · 2017: 8 · 2016: 5 · 2015: 7 · 2014: 7 · 2013: 6 · 2012: 10
FWCI
14.47
Type
journal article
Language
en
Open access
Licence
Locations
  • American Journal of Clinical Nutrition (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
Keywords
orlistat, lipase inhibitors, weight maintenance, weight regain, obesity, hypocaloric diet, long-term weight loss, LDL cholesterol, total cholesterol
MeSH terms
Orlistat, Adult, Behavior Therapy, Cardiovascular Diseases, Dietary Fats, Dose-Response Relationship, Drug, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Lactones, Lipase, Cholesterol, HDL, Male, Obesity, Risk Factors, Weight Loss, Anti-Obesity Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review